Any exercise requiring hip stability may inadvertently engage the adductors
Long arginine 3-IGF-1, abbreviated as IGF-1 LR3 or LR3-IGF-1, is a synthetic protein and lengthened analogue of human insulin-like growth factor 1 (IGF-1).[1][2] It differs from native IGF-1 in that it possesses an arginine instead of a glutamic acid at the third position in its amino acid sequence (arginine 3), and also has an additional 13 amino acids at its N-terminus (MFPAMPLLSLFVN) (long), for a total of 83 amino acids (relative to the 70 of IGF-1).[2] The consequences of these modifications are that IGF-1 LR3 retains the pharmacological activity of IGF-1 as an agonist of the IGF-1 receptor, has very low affinity for the insulin-like growth factor-binding proteins (IGFBPs), and has improved metabolic stability.[1][2] As a result, it is approximately three times more potent than IGF-1,[3] and possesses a significantly longer half-life of about 2030 hours (relative to IGF-1s half-life of about 1215 hours).[4] IGF-1 LR3 Peptide is under active investigation in a number of cell culture and animal models
Preclinical research introduced FOXO4-DRI as a targeted approach for studying senescent cell survival mechanisms by modulating transcription factor interactions rather than global cytotoxic activity
Their studies reveal that BPC-157 provides potent cytoprotection against neural injury and gastrointestinal ulcers.13,14 In a study on rats with persistent gastric ulcers given a high dose of 6-alpha-methylprednisolone, BPC-157 improved gastric ulcer mucosal healing and overcame the inhibitory effects of corticosteroids on the healing process.33 BPC-157 has also demonstrated cytoprotective properties in the gastrointestinal tract
One in ten American adults is now living with some degree of CKD, and kidney disease is the ninth leading cause of death in the United States (NKUDIC 2012
